This is a randomized, multicenter, placebo-controlled, double-blind clinical study in
patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2
Eligible 300 hospitalized patients with confirmed severe SARS-CoV-2 infection will be
randomly assigned (1:1) to receive 14 days treatment of 400 mg carrimycin and standard of
care (SOC) or placebo and SOC.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.